Gefitinib for refractory advanced non-small-cell lung cancer.
Publication
, Journal Article
Tsurutani, J; Ballas, M; Steinberg, SM; Egilsson, V; Dennis, PA
Published in: Lancet
January 28, 2006
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
Lancet
DOI
EISSN
1474-547X
Publication Date
January 28, 2006
Volume
367
Issue
9507
Start / End Page
300
Location
England
Related Subject Headings
- Smoking
- Quinazolines
- Protein Kinase Inhibitors
- Lung Neoplasms
- Humans
- General & Internal Medicine
- Gefitinib
- Female
- Erlotinib Hydrochloride
- Clinical Trials as Topic
Citation
APA
Chicago
ICMJE
MLA
NLM
Tsurutani, J., Ballas, M., Steinberg, S. M., Egilsson, V., & Dennis, P. A. (2006). Gefitinib for refractory advanced non-small-cell lung cancer. Lancet, 367(9507), 300. https://doi.org/10.1016/S0140-6736(06)68064-1
Tsurutani, Junji, Marc Ballas, Seth M. Steinberg, Valgardur Egilsson, and Phillip A. Dennis. “Gefitinib for refractory advanced non-small-cell lung cancer.” Lancet 367, no. 9507 (January 28, 2006): 300. https://doi.org/10.1016/S0140-6736(06)68064-1.
Tsurutani J, Ballas M, Steinberg SM, Egilsson V, Dennis PA. Gefitinib for refractory advanced non-small-cell lung cancer. Lancet. 2006 Jan 28;367(9507):300.
Tsurutani, Junji, et al. “Gefitinib for refractory advanced non-small-cell lung cancer.” Lancet, vol. 367, no. 9507, Jan. 2006, p. 300. Pubmed, doi:10.1016/S0140-6736(06)68064-1.
Tsurutani J, Ballas M, Steinberg SM, Egilsson V, Dennis PA. Gefitinib for refractory advanced non-small-cell lung cancer. Lancet. 2006 Jan 28;367(9507):300.
Published In
Lancet
DOI
EISSN
1474-547X
Publication Date
January 28, 2006
Volume
367
Issue
9507
Start / End Page
300
Location
England
Related Subject Headings
- Smoking
- Quinazolines
- Protein Kinase Inhibitors
- Lung Neoplasms
- Humans
- General & Internal Medicine
- Gefitinib
- Female
- Erlotinib Hydrochloride
- Clinical Trials as Topic